CTOs on the Move

GI Pathology PLLC

www.gipath.com

 
GI Pathology PLLC is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Memphis, TN. To find more information about GI Pathology PLLC, please visit www.gipath.com
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.gipath.com
  • 150 Collins St
    Memphis, TN USA 38112-3814
  • Phone: 901.526.7444

Executives

Name Title Contact Details

Similar Companies

Westwood Executive Search Group

Westwood Executive Search Group is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

isogenix

isogenix is a Chandler, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Luca Technologies

Luca Technologies, Inc. engages in the development of long-term biotechnology-driven solutions to the natural gas market in the United States.

Kelly Productions Inc

Kelly Productions Inc is a Bel Air, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.